Acelyrin, Inc Common Stock Today
| SLRN Stock | USD 4.57 0.07 1.51% |
Performance1 of 100
| Odds Of DistressOver 55
|
ACELYRIN, INC is selling at 4.57 as of the 29th of November 2024; that is 1.51 percent decrease since the beginning of the trading day. The stock's open price was 4.64. ACELYRIN, INC has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for ACELYRIN, INC Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of May 2023 | Category Healthcare | Classification Health Care |
ACELYRIN, INC is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 100.33 M outstanding shares of which 5.73 M shares are at this time shorted by private and institutional investors with about 10.1 trading days to cover. More on ACELYRIN, INC Common
Moving together with ACELYRIN, Stock
Moving against ACELYRIN, Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ACELYRIN, Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Mina JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
ACELYRIN, INC Common (SLRN) is traded on NASDAQ Exchange in USA. It is located in 4149 Liberty Canyon Road, Agoura Hills, CA, United States, 91301 and employs 135 people. ACELYRIN, INC is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 458.49 M. ACELYRIN, INC Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 100.33 M outstanding shares of which 5.73 M shares are at this time shorted by private and institutional investors with about 10.1 trading days to cover.
ACELYRIN, INC generates negative cash flow from operations
Check ACELYRIN, INC Probability Of Bankruptcy
Ownership AllocationACELYRIN, INC holds a total of 100.33 Million outstanding shares. The majority of ACELYRIN, INC Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ACELYRIN, INC Common to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ACELYRIN, INC. Please pay attention to any change in the institutional holdings of ACELYRIN, INC Common as this could imply that something significant has changed or is about to change at the company. Also note that nearly seven million five hundred four thousand three hundred eighty-five invesors are currently shorting ACELYRIN, INC expressing very little confidence in its future performance.
Check ACELYRIN, Ownership Details
ACELYRIN, INC Historical Income Statement
ACELYRIN, Stock Against Markets
ACELYRIN, INC Corporate Management
| Patricia Turney | Chief Officer | Profile | |
| Kenneth Lock | Chief Officer | Profile | |
| Gilbert JD | Principal Officer | Profile | |
| Shephard MD | Senior Development | Profile | |
| Kelly Chow | Chief Officer | Profile | |
| Ron Oyston | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in ACELYRIN, INC Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACELYRIN, INC. If investors know ACELYRIN, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACELYRIN, INC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.33) | Return On Equity (0.42) |
The market value of ACELYRIN, INC Common is measured differently than its book value, which is the value of ACELYRIN, that is recorded on the company's balance sheet. Investors also form their own opinion of ACELYRIN, INC's value that differs from its market value or its book value, called intrinsic value, which is ACELYRIN, INC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACELYRIN, INC's market value can be influenced by many factors that don't directly affect ACELYRIN, INC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACELYRIN, INC's value and its price as these two are different measures arrived at by different means. Investors typically determine if ACELYRIN, INC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACELYRIN, INC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.